| scholarly article | Q13442814 |
| P356 | DOI | 10.1371/JOURNAL.PONE.0190682 |
| P8608 | Fatcat ID | release_bysngnlotvcenocmcilrzll35u |
| P932 | PMC publication ID | 5752038 |
| P698 | PubMed publication ID | 29298347 |
| P50 | author | Martin Grundy | Q88556579 |
| Thomas Jones | Q88556581 | ||
| Nigel Russell | Q100565148 | ||
| Liban Elmi | Q114424734 | ||
| Monica Pallis | Q114424735 | ||
| P2093 | author name string | Michael Hall | |
| Claire Seedhouse | |||
| Adam Graham | |||
| P2860 | cites work | Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function | Q24293924 |
| Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia | Q24313505 | ||
| The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2 | Q24317954 | ||
| Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | Q27674674 | ||
| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 | ||
| Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis | Q28139061 | ||
| An inhibitor of Bcl-2 family proteins induces regression of solid tumours | Q29547595 | ||
| An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 | Q29614563 | ||
| Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. | Q33806087 | ||
| BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. | Q34289202 | ||
| Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia | Q34392488 | ||
| The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite | Q34517403 | ||
| Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells | Q34773140 | ||
| Systematic discovery of multicomponent therapeutics | Q35147474 | ||
| Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. | Q35250940 | ||
| Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. | Q35337927 | ||
| Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). | Q35543223 | ||
| Rapid turnover of mcl-1 couples translation to cell survival and apoptosis | Q35695499 | ||
| Rational Combinations of Targeted Agents in AML | Q35750491 | ||
| Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B. | Q35800840 | ||
| Cell death signaling and anticancer therapy | Q35972102 | ||
| CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies | Q36170136 | ||
| Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) | Q36349985 | ||
| Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia | Q36544778 | ||
| BAD Enables Ceramide to Signal Apoptosis via Ras and Raf-1 | Q59123101 | ||
| The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques | Q71078421 | ||
| Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A | Q77985300 | ||
| Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells | Q89700494 | ||
| MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma | Q36546300 | ||
| MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex | Q36706340 | ||
| Resistance to HSP90 inhibition involving loss of MCL1 addiction. | Q36762412 | ||
| Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins | Q36984373 | ||
| Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A. | Q37061433 | ||
| MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts | Q37425601 | ||
| CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. | Q37445828 | ||
| A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition | Q37670967 | ||
| Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells | Q37725409 | ||
| Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. | Q38172752 | ||
| Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript | Q38319141 | ||
| Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. | Q38322943 | ||
| Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? | Q38664735 | ||
| The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models | Q38736457 | ||
| Frontline treatment of acute myeloid leukemia in adults | Q38767583 | ||
| The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. | Q38826234 | ||
| FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia | Q38892684 | ||
| Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia | Q39006397 | ||
| Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity. | Q39016220 | ||
| Bromodomain inhibitors and cancer therapy: From structures to applications | Q39027056 | ||
| Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. | Q39033630 | ||
| BH3 profiling in whole cells by fluorimeter or FACS | Q39162409 | ||
| Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. | Q39300586 | ||
| Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation | Q39895438 | ||
| CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells | Q39950924 | ||
| Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. | Q40024347 | ||
| Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. | Q40150524 | ||
| Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation | Q40383692 | ||
| The search for synergy: a critical review from a response surface perspective. | Q40417895 | ||
| Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. | Q41009977 | ||
| Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis | Q41065043 | ||
| Evaluation and critical assessment of putative MCL-1 inhibitors. | Q41964206 | ||
| The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. | Q42064781 | ||
| Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells | Q42317487 | ||
| Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. | Q42906307 | ||
| Mitochondrial membrane sensitivity to depolarization in acute myeloblastic leukemia is associated with spontaneous in vitro apoptosis, wild-type TP53, and vicinal thiol/disulfide status | Q43660454 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| apoptotic process | Q14599311 | ||
| P304 | page(s) | e0190682 | |
| P577 | publication date | 2018-01-03 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling | |
| P478 | volume | 13 |
| Q64899051 | A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. |
| Q64109908 | Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism |
| Q61454350 | Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells |
| Q57073789 | Overexpression of MYCT1 Inhibits Proliferation and Induces Apoptosis in Human Acute Myeloid Leukemia HL-60 and KG-1a Cells and |
| Q89556034 | STAT5-dependent regulation of CDC25A by miR-16 controls proliferation and differentiation in FLT3-ITD acute myeloid leukemia |
Search more.